NEW YORK - Directors of Pfizer Inc. met yesterday to consider the acquisition of rival drug maker Wyeth in a deal that could be worth more than $65 billion, said people with knowledge of the talks. Pfizer's CEO, Jeffrey Kindler, would lead the combined companies, two people said.